Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Letter to the Editor

Response to Athyros and Colleagues: Inflammation and LDL Reduction

Author(s): Rodrigo Damián García*, Joana Antonela Asensio, Diahann Jeanette Perdicaro and María de Los Ángeles Peral

Volume 21, Issue 1, 2023

Published on: 27 January, 2023

Page: [71 - 72] Pages: 2

DOI: 10.2174/1570161121666230118115539

Price: $65

« Previous Next »
[1]
Athyros Vg, Sficas G, Koumaras C. Inflammation and LDL reduction. Curr Vasc Pharmacol 2022.
[http://dx.doi.org/10.2174/1570161120666221004150503]
[2]
García RD, Asensio JA, Perdicaro DJ, de los Ángeles Peral M. The role of inflammation as a preponderant risk factor in cardiovascular diseases. Curr Vasc Pharmacol 2022; 20(3): 244-59.
[http://dx.doi.org/10.2174/1570161120666220201160038] [PMID: 35105294]
[3]
Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359(21): 2195-207.
[http://dx.doi.org/10.1056/NEJMoa0807646] [PMID: 18997196]
[4]
Eckard AR, McComsey GA. The role of statins in the setting of HIV infection. Curr HIV/AIDS Rep 2015; 12(3): 305-12.
[http://dx.doi.org/10.1007/s11904-015-0273-9] [PMID: 26126687]
[5]
Eckard AR, Jiang Y, Debanne SM, Funderburg NT, McComsey GA. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis 2014; 209(8): 1156-64.
[http://dx.doi.org/10.1093/infdis/jiu012] [PMID: 24415784]
[6]
Paraskevas KI. Statin treatment for rheumatoid arthritis: a promising novel indication. Clin Rheumatol 2008; 27(3): 281-7.
[http://dx.doi.org/10.1007/s10067-007-0806-8] [PMID: 18066611]
[7]
Ballarano CA, Frishman WH. Cardiovascular disease in patients with systemic lupus erythematosus. Cardiol Rev 2021; 29(6): 323-7.
[http://dx.doi.org/10.1097/CRD.0000000000000383] [PMID: 34609986]
[8]
Vallakati A, Reddy S, Dunlap ME, Taylor DO. Impact of statin use after heart transplantation: a meta-analysis. Circ Heart Fail 2016; 9(10)e003265
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.116.003265] [PMID: 27729391]
[9]
Croce K, Libby P. Stirring the soup of innate immunity in the acute coronary syndromes. Eur Heart J 2010; 31(12): 1430-2.
[http://dx.doi.org/10.1093/eurheartj/ehq085] [PMID: 20447946]
[10]
Cimmino G, Loffredo FS, Morello A, et al. Immune-inflammatory activation in acute coronary syndromes: a look into the heart of unstable coronary plaque. Curr Cardiol Rev 2017; 13(2): 110-7.
[PMID: 27758696]
[11]
Badimon JJ, Ibanez B, Cimmino G. Genesis and dynamics of atherosclerotic lesions: implications for early detection. Cerebrovasc Dis 2009; 27 (Suppl. 1): 38-47.
[http://dx.doi.org/10.1159/000200440] [PMID: 19342832]
[12]
Shanahan CM, Furmanik M. Endoplasmic reticulum stress in arterial smooth muscle Cells: a novel regulator of vascular disease. Curr Cardiol Rev 2017; 13(2): 94-105.
[PMID: 27758694]
[13]
Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377(12): 1119-31.
[http://dx.doi.org/10.1056/NEJMoa1707914] [PMID: 28845751]
[14]
Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 2019; 381(26): 2497-505.
[http://dx.doi.org/10.1056/NEJMoa1912388] [PMID: 31733140]
[15]
Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013; 61(4): 404-10.
[http://dx.doi.org/10.1016/j.jacc.2012.10.027] [PMID: 23265346]
[16]
Ulander L, Tolppanen H, Hartman O, et al. Hydroxychloroquine reduces interleukin-6 levels after myocardial infarction: The randomized, double-blind, placebo-controlled OXI pilot trial. Int J Cardiol 2021; 337: 21-7.
[http://dx.doi.org/10.1016/j.ijcard.2021.04.062] [PMID: 33961943]
[17]
Aday AW, Ridker PM. Targeting residual inflammatory risk: a shifting paradigm for atherosclerotic disease. Front Cardiovasc Med 2019; 6: 16.
[http://dx.doi.org/10.3389/fcvm.2019.00016] [PMID: 30873416]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy